Compare GraniteShares 2x Long NVDA Daily ETF (NVDL) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GraniteShares 2x Long NVDA Daily ETF vs Tango Therapeutics Inc. — how do they compare? GraniteShares 2x Long NVDA Daily ETF trades at $33.19 (market cap $3.52B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: GraniteShares 2x Long NVDA Daily ETF and Tango Therapeutics Inc. are close in size by market cap, and Tango Therapeutics Inc. is more actively traded (9,619,106 versus 6,205,788). Which is the better fit depends on your goals — on Pluang, investors hold GraniteShares 2x Long NVDA Daily ETF for 15 Days and Tango Therapeutics Inc. for 0 Days on average.
| NVDL | TNGX | |
|---|---|---|
Market Cap | $3.52B | $3.75B |
Volume | 6,205,788 | 9,619,106 |
Sector | Leveraged / Inverse | Health |
52-Week High | $43.02 | $32.90 |
52-Week Low | $21.76 | $7.50 |
Typical Hold Time | 15 Days | 0 Days |
Enterprise Value | — | $2.77B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NVDL, the GraniteShares 2x Long NVDA Daily ETF, trades at $36.58 with a 1.81% daily gain. Technical indicators show a bullish overall signal with mixed moving averages and neutral oscillators. The ETF tracks Nvidia's performance with 2x daily leverage, though recent articles highlight it underperformed NVDA's 22.21% one-year return with only 17.21%. Recent news focuses on Nvidia's strong earnings and AI leadership driving optimism.
The outlook remains tied to Nvidia's AI dominance and earnings momentum, offering leveraged exposure to chip sector growth. Key risks include leverage decay, tracking error, and Nvidia's high valuation sensitivity. Investors should weigh the ETF's daily reset mechanism against long-term holding costs amid volatile tech markets.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About GraniteShares 2x Long NVDA Daily ETF
NVDL is a leveraged ETF that seeks daily investment results corresponding to 200% (2x) of the daily performance of NVIDIA Corporation (NVDA) stock. It is designed as a tactical trading tool for investors with a strong bullish (long) view on NVDA. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment, as its performance over longer periods may significantly deviate from two times the performance of the NVDA stock.
Read more on NVDL →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
